Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mi Jun Keng

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
BMJ Open|March 6, 2020
How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models' projections for EnglandGwyn Bevan, Chiara De Poli, Mi Jun Keng, et al.
Pharmacoeconomics|November 10, 2023
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A TutorialJunwen Zhou, Claire Williams, Mi Jun Keng, et al.
Diabetes, Obesity & Metabolism|December 6, 2021
Decrements in health-related quality of life associated with adverse events in people with diabetesMi Jun Keng, Jose Leal, Louise Bowman, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costsMi Jun Keng, Apostolos Tsiachristas, Jose Leal, et al.
Diabetes, Obesity & Metabolism|June 9, 2022
Hospital costs associated with adverse events in people with diabetes in the UKMi Jun Keng, Jose Leal, Louise Bowman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 1, 2022
Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial CohortMi Jun Keng, Jose Leal, Marion Mafham, et al.
Journal of Comparative Effectiveness Research|August 12, 2025
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myelomaJianming He, Karen Chiang, Xiwu Lin, et al.
Journal of the American Heart Association|September 26, 2023
Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United StatesJuliana Nga Man Lui, Claire Williams, Mi Jun Keng, et al.
Advances in Therapy|March 12, 2026
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia GravisSaiju Jacob, Mahmoud Hashim, Brian Hutton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2024
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood ChallengeJames Altunkaya, Xinyu Li, Amanda Adler, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
BMJ Open|March 6, 2020
How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models' projections for EnglandGwyn Bevan, Chiara De Poli, Mi Jun Keng, et al.
Pharmacoeconomics|November 10, 2023
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A TutorialJunwen Zhou, Claire Williams, Mi Jun Keng, et al.
Diabetes, Obesity & Metabolism|December 6, 2021
Decrements in health-related quality of life associated with adverse events in people with diabetesMi Jun Keng, Jose Leal, Louise Bowman, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costsMi Jun Keng, Apostolos Tsiachristas, Jose Leal, et al.
Diabetes, Obesity & Metabolism|June 9, 2022
Hospital costs associated with adverse events in people with diabetes in the UKMi Jun Keng, Jose Leal, Louise Bowman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 1, 2022
Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial CohortMi Jun Keng, Jose Leal, Marion Mafham, et al.
Journal of Comparative Effectiveness Research|August 12, 2025
Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myelomaJianming He, Karen Chiang, Xiwu Lin, et al.
Journal of the American Heart Association|September 26, 2023
Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United StatesJuliana Nga Man Lui, Claire Williams, Mi Jun Keng, et al.
Advances in Therapy|March 12, 2026
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia GravisSaiju Jacob, Mahmoud Hashim, Brian Hutton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 10, 2024
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood ChallengeJames Altunkaya, Xinyu Li, Amanda Adler, et al.
Pageof 1